Bristol Myers Squibb (NYSE: BMY) had its price target boosted by Jefferies Group from $39.00 to $41.00 in a research report released on Tuesday morning. Jefferies Group currently has a buy rating on the stock.
“2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers’ mid to long term growth. We believe that Eliquis will beat launch expectations providing meaningful earnings momentum, whilst several major R&D catalysts (anti-PD1 and Yervoy) further expand the PE multiple. We reiterate our Buy rating and have increased our PT to $41 (from $39).,” the firm’s analyst wrote.
Several other analysts have also recently commented on the stock. Analysts at TheStreet reiterated a buy rating on shares of Bristol Myers Squibb in a research note to investors on Friday, February 8th. Separately, analysts at Zacks reiterated a neutral rating on shares of Bristol Myers Squibb in a research note to investors on Friday, January 25th. They now have a $38.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Bristol Myers Squibb from $34.00 to $36.00 in a research note to investors on Friday, January 25th. They now have a neutral rating on the stock.
Six investment analysts have rated the stock with a buy rating, one has issued an overweight rating, thirteen have assigned a hold rating, and one has assigned a sell rating to the company’s stock. Bristol Myers Squibb currently has a consensus rating of overweight and an average price target of $35.39.
Bristol Myers Squibb traded up 1.27% on Tuesday, hitting $36.58. Bristol Myers Squibb has a 1-year low of $30.64 and a 1-year high of $37.09. The stock’s 50-day moving average is currently $34.88. The company has a market cap of $60.382 billion and a price-to-earnings ratio of 31.11.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.